Lanfranco Leo

Lanfranco Leo is a senior research investigator at the University of Pennsylvania since September 2023, previously serving as principal investigator at SwanBio Therapeutics from July 2020 to September 2023. At SwanBio, Lanfranco built and led AAV9 gene therapy pre-IND programs for rare neurological diseases, managing a team of scientists and composing research results for key stakeholders. Prior to this, Lanfranco held the position of translational research scientist at the University of Pennsylvania, where five independent AAV gene therapy programs were developed for ocular neurodegenerative diseases. With a Ph.D. in Neuroscience from Drexel University, a Master's in Pharmaceutical Biotechnology, and a Bachelor's in Biotechnology from Sapienza Università di Roma, Lanfranco has developed expertise in gene therapy, translational science, and neurodegeneration research throughout a diverse academic and professional career.